The pandemic proved that mRNA-based vaccines could be developed, manufactured, and distributed globally in record time. But the real promise of mRNA is only beginning to unfold. Developers are now targeting mRNA applications across therapeutic areas from rare disease and oncology to gene and cell therapy.
In this article, BioCina experts explore the post-pandemic future of mRNA and share strategies to unlock its next phase of therapeutic potential. Topics covered include:
- Emerging applications in protein replacement, antibody therapy, and gene editing
- How mRNA is simplifying adoptive cell therapy and ex vivo delivery
- Design and manufacturing considerations for novel RNA formats
- Challenges in scale-up, regulatory alignment, and global delivery
- How BioCina enables mRNA programs with integrated, flexible GMP manufacturing
With advanced capabilities in mRNA, pDNA, LNP encapsulation, and fill–finish, BioCina is uniquely positioned to support the next generation of mRNA-based therapies.